Two healthcare sector companies Pfizer Inc. (NYSE:PFE) and BioNTech SE (Nasdaq:BNTX) revealed that the first participants in the Phase 1/2 clinical trial for the vaccine of BioNTech BNT162 to prevent coronavirus infection, have been dosed in the United States.
Moreover, this study is part of a global development program and is designed for the establishment of the safety, immunogenicity as well as the optimum dose level of four mRNA vaccine candidates which will be assessed in a single, continuous clinical study.
In Germany, the dosing of the first cohort of this developmental program was completed last week.
Pfizer also disclosed that this development program includes four vaccine candidates and each candidate indicating a different combination of mRNA format and target antigen.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.
